Riskpilot← Back to searchSign inGet full accessPharma Way AB
ABActiveOrg 5591463400Långängsvägen 24Wholesale of beverages · NACE 4634Est. 20181-4 employees
Revenue 2024
SEK 1,7M
+35% vs 2023
EBITDA margin
-278.5%
+26% vs 2023
Equity ratio
16.9%
Financial strength
Net profit 2024
SEK -5,3M
+24% vs 2023
| Revenue | SEK 1,7M | +35% |
| EBITDA | SEK -4,7M | +26% |
| Net profit | SEK -5,3M | +24% |
| Total assets | SEK 2M | -44% |
| Equity | SEK 336K | +3% |
| Employees | — | — |
Legal name
Pharma Way AB
Org number
5591463400
Legal form
Aktiebolag
NACE code
4634 · Wholesale of beverages
Founded
23 januari 2018
Share capital
SEK 672 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Folkesson, Claes Micael Joachim Österlund, Dan Mårten Firman tecknas två i förening av ledamöterna
Company purpose
Konsultation och handel inom egenvård och läkemedel samt konsultation och handel inom vin, sprit och öl produkter.
Address
Långängsvägen 24
Email
info@pharma-way.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 104 | 824 | 1 542 | 1 691 | 4 305 | 1 251 | 1 688 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −111 | −1 638 | −1 148 | −2 075 | −5 305 | −6 316 | −4 701 |
| Depreciation & amort. | −0 | −0 | −38 | −214 | −398 | −472 | −484 |
| EBIT | −111 | −1 638 | −1 186 | −2 289 | −5 703 | −6 788 | −5 185 |
| Net financials | — | −7 | −8 | −115 | −104 | −132 | −64 |
| Profit before tax | −111 | −1 645 | −1 194 | −2 404 | −5 807 | −6 918 | −5 250 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −111 | −1 645 | −1 194 | −2 404 | −5 807 | −6 918 | −5 250 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 600 | 1 052 | 2 191 | 3 396 | 2 804 | 3 546 | 1 983 |
| Equity | 59 | −1 586 | 140 | −344 | −1 593 | 327 | 336 |
| Long-term debt | 0 | 183 | 1 300 | 1 223 | 3 513 | 2 567 | 880 |
| Short-term debt | 541 | 2 454 | 751 | 2 517 | 883 | 652 | 767 |
| Total debt | 541 | 2 637 | 2 051 | 3 740 | 4 396 | 3 219 | 1 647 |
EBITDA margin
-278.5%
This company
15.8%
Market median
-1863% vs market
20182024
Equity ratio
16.9%
This company
38.2%
Market median
-56% vs market
20182024
Return on equity
-1562.5%
This company
18.4%
Market median
-8592% vs market
20182024
Net profit margin
-311.0%
This company
8.1%
Market median
-3940% vs market
20182024
Asset turnover
0.85×
This company
1.12×
Market median
+24% vs market
20182024
Debt / equity
4.90×
This company
0.62×
Market median
-690% vs market
20182024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 | — | — |
| Audit | 2021 | — | — | |
DM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharma Way AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claes Micael Joachim Folkesson | Deputy Chief Executive Officer | 0 companies |
| Ragnar Carl Gudmund T Santesson | Audit | 0 companies |
| Dan Mårten Österlund | Chief Executive Officer | 0 companies |
| Karin Marie Österlund | Deputy Board Member | 0 companies |
| Torben Jörgensen | Board of Directors | 0 companies |
| Anna Margareta Folkesson | Deputy Board Member | 0 companies |
| Peter Györki | Chairman | 0 companies |
| Lars Ulrik Östen Cheddi Liljeström | Board of Directors | 0 companies |